Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393209 · ClinicalTrials.gov registry record · Phase 1
Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02393209 is a Phase 1 study that was terminated before completion, run by Millennium Pharmaceuticals. The registered enrollment target is 14 participants.
The verdict
NCT02393209, a Phase 1 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the recommended phase 2 dose (RP2D) of TAK-117 when administered in combination with docetaxel in participants with non-small cell lung cancer (NSCLC) and to evaluate efficacy, safety, and tolerability of TAK-117 administered alone and in combination with docetaxel at the RP2D in participants with locally advanced or metastatic non-small cell lung cancer.
Interventions
- DRUG Docetaxel
- DRUG TAK-117
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-06-03 |
| Est. Completion | 2017-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02393209
The ClinicalTrials.gov registry entry for NCT02393209 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT02393209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02393209 about?
NCT02393209 is a clinical study titled "Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer". The purpose of this study is to determine the recommended phase 2 dose (RP2D) of TAK-117 when administered in combination with docetaxel in participants with non-small cell lung cancer (NSCLC) and to evaluate efficacy, safety, and tolerability of TAK-117 administered alone and in combination with do...
What is the current status of trial NCT02393209?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2015-06-03. Estimated completion is 2017-01-20.
What interventions are being tested in trial NCT02393209?
The interventions under investigation include: Docetaxel (DRUG), TAK-117 (DRUG).
Who is sponsoring clinical trial NCT02393209?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.